Interest in Switching to On-Demand HIV Pre-Exposure Prophylaxis (PrEP) Among Australian Users of Daily PrEP: An Online Survey

Abstract We surveyed 970 PrEPX study participants to evaluate interest in switching from daily to on-demand PrEP in a study setting. Interested respondents (n = 469, 48%) more commonly reported PrEP cessation (adjusted odds ratio [aOR], 3.0; P < .001), difficulty with adherence (aOR, 1.6; P = .029), infrequent sex (aOR, 3.7; P < .001), and toxicity concerns (aOR, 2.7; P < .001).

[1]  Brian L. Price,et al.  Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection , 2019, JAMA.

[2]  S. McCormack,et al.  BHIVA/BASHH guidelines on the use of HIV pre–exposure prophylaxis (PrEP) 2018 , 2019, HIV medicine.

[3]  B. Vuylsteke,et al.  Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project , 2018, Journal of acquired immune deficiency syndromes.

[4]  C. Delaugerre,et al.  Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. , 2018, AIDS.

[5]  Huldrych F. Günthard,et al.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel , 2018, JAMA.

[6]  M. Boyd,et al.  Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018 , 2018, Journal of virus eradication.

[7]  T. Holtz,et al.  Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Boyd,et al.  Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018 , 2018, Journal of virus eradication.

[9]  A. Hogewoning,et al.  Men who have sex with men more often chose daily than event‐driven use of pre‐exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam , 2018, Journal of the International AIDS Society.

[10]  C. Tremblay,et al.  Costs and benefits of On-Demand HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men Analysis of the ANRS IPERGAY study with a one-year follow-up. , 2018, AIDS.

[11]  M. Boffito,et al.  InterPrEP: internet‐based pre‐exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London – analysis of pharmacokinetics, safety and outcomes , 2018, HIV medicine.

[12]  A. McNulty,et al.  Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project , 2017, Front. Public Health.

[13]  Lisa P. Barrett,et al.  Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis , 2017, Canadian Medical Association Journal.

[14]  M. Wainberg,et al.  Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. , 2017, The lancet. HIV.

[15]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[16]  D. Glidden,et al.  Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis , 2014, AIDS.

[17]  L. Grohskopf,et al.  Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco , 2011, PloS one.